Drug Profile
COVID-2019 immune globulins (Equine) - Emergent BioSolutions
Alternative Names: Anti-SARS-CoV-2 immune globulin intravenous (Equine); COVID-19 immune globulins (Equine); COVID-EIGLatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Emergent BioSolutions
- Class Antivirals; Immunoglobulin fragments
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in COVID-2019-infections in USA (Parenteral)
- 27 Oct 2020 Phase-I clinical trials in COVID-2019 infections in USA (Parenteral) (Emergent BioSolutions pipeline, October 2020)
- 27 Jul 2020 Emergent BioSolutions plans a phase II trial for COVID-2019 infections (Parenteral) in 2020